Skip to content
Find a Provider

Lisa D. Reichman, M.D.

Contact

Office (585) 275-5871
Fax (585) 442-9328

About Me

Certified Specialties

Internal Medicine - American Board of Internal Medicine

Faculty Appointments

Professor Emeritus - Department of Medicine, Infectious Diseases (SMD)

Credentials

Education

MD | Univ Rochester Sch Med/Dent. Medicine. 1984

MS | University of Rochester. Biology. 1980

BA | University of Rochester. Biology. 1979

Awards

John Carey Junior Investigator Award, from the NIH-sponsored Adult AIDS Clinical Trials Group (given to one junior investigator per year) 1997

Alpha Omega Alpha 1984

Bryce Collier Prize 1984

Janet M. Glasgow Memorial Achievement Citation, awarded by the AMWA 1984

Rudolph Angell Award 1984

Doctor of Medicine, awarded with honor, University of Rochester (given to 3 students in the graduating class) 1984

Publications

Journal Articles

Combination antiretroviral treatment for women previously treated only in pregnancy: week 24 results of AIDS clinical trials group protocol a5227.

Vogler MA, Smeaton LM, Wright RL, Cardoso SW, Sanchez J, Infante R, Moran LE, Godfrey C, Demeter LM, Johnson VA

Journal of acquired immune deficiency syndromes : JAIDS.. 2014 April 1565 (5):542-50. Epub 1900 01 01.

Discordant associations between SLCO1B1 521T?C and plasma levels of ritonavir-boosted protease inhibitors in AIDS clinical trials group study A5146.

Zhang X, Tierney C, Albrecht M, Demeter LM, Morse G, DiFrancesco R, Dykes C, Jiang H, Haas DW

Therapeutic drug monitoring.. 2013 April 35 (2):209-16. Epub 1900 01 01.

Nonnucleoside reverse transcriptase inhibitor-resistant HIV is stimulated by efavirenz during early stages of infection.

Wang J, Zhang G, Bambara RA, Li D, Liang H, Wu H, Smith HM, Lowe NR, Demeter LM, Dykes C

Journal of virology.. 2011 October 85 (20):10861-73. Epub 08/10/2011.

Augmented HIV-specific interferon-gamma responses, but impaired lymphoproliferation during interruption of antiretroviral treatment initiated in primary HIV infection.

Connick E, Bosch RJ, Aga E, Schlichtemeier R, Demeter LM, Volberding P,

Journal of acquired immune deficiency syndromes : JAIDS.. 2011 September 158 (1):1-8. Epub 1900 01 01.

Sequences in the U3 region of human immunodeficiency virus 1 improve efficiency of minus strand transfer in infected cells.

Piekna-Przybylska D, Dykes C, Demeter LM, Bambara RA

Virology.. 2011 February 20410 (2):368-74. Epub 12/30/2010.

A randomized clinical trial evaluating therapeutic drug monitoring (TDM) for protease inhibitor-based regimens in antiretroviral-experienced HIV-infected individuals: week 48 results of the A5146 study.

Albrecht M, Mukherjee AL, Tierney C, Morse GD, Dykes C, Klingman KL, Demeter LM

HIV clinical trials.. 2011 12 (4):201-14. Epub 1900 01 01.

Human immunodeficiency virus type 1 protease inhibitor drug-resistant mutants give discordant results when compared in single-cycle and multiple-cycle fitness assays.

Dykes C, Wu H, Sims M, Holden-Wiltse J, Demeter LM

Journal of clinical microbiology.. 2010 November 48 (11):4035-43. Epub 09/08/2010.

HIV-1 reverse transcriptase connection domain mutations: dynamics of emergence and implications for success of combination antiretroviral therapy.

von Wyl V, Ehteshami M, Demeter LM, Bürgisser P, Nijhuis M, Symons J, Yerly S, Böni J, Klimkait T, Schuurman R, Ledergerber B, Götte M, Günthard HF,

Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.. 2010 September 151 (5):620-8. Epub 1900 01 01.

Reduced fitness in cell culture of HIV-1 with nonnucleoside reverse transcriptase inhibitor-resistant mutations correlates with relative levels of reverse transcriptase content and RNase H activity in virions.

Wang J, Bambara RA, Dykes C

Journal of virology.. 2010 September 84 (18):9377-89. Epub 06/30/2010.

Prevalence of primary resistance at baseline in acutely and recently infected subjects enrolled in AIDS clinical trials group protocol 371.

Dykes C, Mukherjee AL, Bosch RJ, Connick E, Volberding PA, Demeter LM

Journal of acquired immune deficiency syndromes : JAIDS.. 2010 September 55 (1):132-4. Epub 1900 01 01.

Quality assessment for therapeutic drug monitoring in AIDS Clinical Trials Group (ACTG 5146): a multicenter clinical trial.

Difrancesco R, Rosenkranz S, Mukherjee AL, Demeter LM, Jiang H, Dicenzo R, Dykes C, Rinehart A, Albrecht M, Morse GD

Therapeutic drug monitoring.. 2010 August 32 (4):458-66. Epub 1900 01 01.

The non-nucleoside reverse transcriptase inhibitor efavirenz stimulates replication of human immunodeficiency virus type 1 harboring certain non-nucleoside resistance mutations.

Wang J, Liang H, Bacheler L, Wu H, Deriziotis K, Demeter LM, Dykes C

Virology.. 2010 July 5402 (2):228-37. Epub 04/18/2010.

vFitness: a web-based computing tool for improving estimation of in vitro HIV-1 fitness experiments.

Ma J, Dykes C, Wu T, Huang Y, Demeter L, Wu H

BMC bioinformatics.. 2010 May 1811 :261. Epub 05/18/2010.

Epidemiological and biological evidence for a compensatory effect of connection domain mutation N348I on M184V in HIV-1 reverse transcriptase.

von Wyl V, Ehteshami M, Symons J, Bürgisser P, Nijhuis M, Demeter LM, Yerly S, Böni J, Klimkait T, Schuurman R, Ledergerber B, Götte M, Günthard HF,

The Journal of infectious diseases.. 2010 April 1201 (7):1054-62. Epub 1900 01 01.

No evidence for decay of the latent reservoir in HIV-1-infected patients receiving intensive enfuvirtide-containing antiretroviral therapy.

Gandhi RT, Bosch RJ, Aga E, Albrecht M, Demeter LM, Dykes C, Bastow B, Para M, Lai J, Siliciano RF, Siliciano JD, Eron JJ,

The Journal of infectious diseases.. 2010 January 15201 (2):293-6. Epub 1900 01 01.

A randomized, placebo-controlled trial of abacavir intensification in HIV-1-infected adults with virologic suppression on a protease inhibitor-containing regimen.

Hammer SM, Ribaudo H, Bassett R, Mellors JW, Demeter LM, Coombs RW, Currier J, Morse GD, Gerber JG, Martinez AI, Spreen W, Fischl MA, Squires KE,

HIV clinical trials.. 2010 11 (6):312-24. Epub 1900 01 01.

Antiretroviral therapy in acute and recent HIV infection: a prospective multicenter stratified trial of intentionally interrupted treatment.

Volberding P, Demeter L, Bosch RJ, Aga E, Pettinelli C, Hirsch M, Vogler M, Martinez A, Little S, Connick E,

AIDS.. 2009 September 2423 (15):1987-95. Epub 1900 01 01.

Differential equation modeling of HIV viral fitness experiments: model identification, model selection, and multimodel inference.

Miao H, Dykes C, Demeter LM, Wu H

Biometrics.. 2009 March 65 (1):292-300. Epub 05/28/2008.

A randomized trial of therapeutic drug monitoring of protease inhibitors in antiretroviral-experienced, HIV-1-infected patients.

Demeter LM, Jiang H, Mukherjee AL, Morse GD, DiFrancesco R, DiCenzo R, Dykes C, Sista P, Bacheler L, Klingman K, Rinehart A, Albrecht M

AIDS.. 2009 January 2823 (3):357-68. Epub 1900 01 01.

Modeling and estimation of kinetic parameters and replicative fitness of HIV-1 from flow-cytometry-based growth competition experiments.

Miao H, Dykes C, Demeter LM, Cavenaugh J, Park SY, Perelson AS, Wu H

Bulletin of mathematical biology.. 2008 August 70 (6):1749-71. Epub 07/22/2008.

Association of efavirenz hypersusceptibility with virologic response in ACTG 368, a randomized trial of abacavir (ABC) in combination with efavirenz (EFV) and indinavir (IDV) in HIV-infected subjects with prior nucleoside analog experience.

Demeter LM, DeGruttola V, Lustgarten S, Bettendorf D, Fischl M, Eshleman S, Spreen W, Nguyen BY, Koval CE, Eron JJ, Hammer S, Squires K

HIV clinical trials.. 2008 9 (1):11-25. Epub 1900 01 01.

The design and implementation of A5146, a prospective trial assessing the utility of therapeutic drug monitoring using an inhibitory quotient in antiretroviral-experienced HIV-infected patients.

Demeter LM, Mukherjee AL, DiFrancesco R, Jiang H, DiCenzo R, Bastow B, Rinehart AR, Morse GD, Albrecht M

HIV clinical trials.. 2008 9 (1):61-72. Epub 1900 01 01.

Clinical significance of human immunodeficiency virus type 1 replication fitness.

Dykes C, Demeter LM

Clinical microbiology reviews.. 2007 October 20 (4):550-78. Epub 1900 01 01.

Randomized open-label trial of two simplified, class-sparing regimens following a first suppressive three or four-drug regimen.

Fischl MA, Collier AC, Mukherjee AL, Feinberg JE, Demeter LM, Tebas P, Giuliano M, Dehlinger M, Garren K, Brizz B, Bassett R

AIDS.. 2007 January 3021 (3):325-33. Epub 1900 01 01.

HIV-1 viral load assays for resource-limited settings.

Fiscus SA, Cheng B, Crowe SM, Demeter L, Jennings C, Miller V, Respess R, Stevens W,

PLoS medicine.. 2006 October 3 (10):e417. Epub 1900 01 01.

Relative replication fitness of efavirenz-resistant mutants of HIV-1: correlation with frequency during clinical therapy and evidence of compensation for the reduced fitness of K103N + L100I by the nucleoside resistance mutation L74V.

Koval CE, Dykes C, Wang J, Demeter LM

Virology.. 2006 September 15353 (1):184-92. Epub 06/21/2006.

Prevalence of human papillomavirus genotypes and related abnormalities of cervical cytological results among HIV-1-infected women in Rochester, New York.

Luque AE, Jabeen M, Messing S, Lane CA, Demeter LM, Rose RC, Reichman RC

The Journal of infectious diseases.. 2006 August 15194 (4):428-34. Epub 07/13/2006.

HIV-1 reverse transcriptase mutants resistant to nonnucleoside reverse transcriptase inhibitors do not adversely affect DNA synthesis: pre-steady-state and steady-state kinetic studies.

Domaoal RA, Bambara RA, Demeter LM

Journal of acquired immune deficiency syndromes : JAIDS.. 2006 August 142 (4):405-11. Epub 1900 01 01.

Evaluation of a multiple-cycle, recombinant virus, growth competition assay that uses flow cytometry to measure replication efficiency of human immunodeficiency virus type 1 in cell culture.

Dykes C, Wang J, Jin X, Planelles V, An DS, Tallo A, Huang Y, Wu H, Demeter LM

Journal of clinical microbiology.. 2006 June 44 (6):1930-43. Epub 1900 01 01.

The HIV-1 reverse transcriptase mutants G190S and G190A, which confer resistance to non-nucleoside reverse transcriptase inhibitors, demonstrate reductions in RNase H activity and DNA synthesis from tRNA(Lys, 3) that correlate with reductions in replication efficiency.

Wang J, Dykes C, Domaoal RA, Koval CE, Bambara RA, Demeter LM

Virology.. 2006 May 10348 (2):462-74. Epub 02/28/2006.

Modeling and estimation of replication fitness of human immunodeficiency virus type 1 in vitro experiments by using a growth competition assay.

Wu H, Huang Y, Dykes C, Liu D, Ma J, Perelson AS, Demeter LM

Journal of virology.. 2006 March 80 (5):2380-9. Epub 1900 01 01.

HIV-specific cytotoxic cell frequencies measured directly ex vivo by the Lysispot assay can be higher or lower than the frequencies of IFN-gamma-secreting cells: anti-HIV cytotoxicity is not generally impaired relative to other chronic virus responses.

Snyder-Cappione JE, Divekar AA, Maupin GM, Jin X, Demeter LM, Mosmann TR

The Journal of immunology : official journal of the American Association of Immunologists.. 2006 February 15176 (4):2662-8. Epub 1900 01 01.

Update on the pharmacokinetic aspects of antiretroviral agents: implications in therapeutic drug monitoring.

Slish JC, Catanzaro LM, Ma Q, Okusanya OO, Demeter L, Albrecht M, Morse GD

Current pharmaceutical design.. 2006 12 (9):1129-45. Epub 1900 01 01.

Identification of a preferred region for recombination and mutation in HIV-1 gag.

Dykes C, Balakrishnan M, Planelles V, Zhu Y, Bambara RA, Demeter LM

Virology.. 2004 September 1326 (2):262-79. Epub 1900 01 01.

Structural and biochemical effects of human immunodeficiency virus mutants resistant to non-nucleoside reverse transcriptase inhibitors.

Domaoal RA, Demeter LM

The international journal of biochemistry & cell biology.. 2004 September 36 (9):1735-51. Epub 1900 01 01.

HIV-1 drug resistance in subjects with advanced HIV-1 infection in whom antiretroviral combination therapy is failing: a substudy of AIDS Clinical Trials Group Protocol 388.

Demeter LM, Ribaudo HJ, Erice A, Eshleman SH, Hammer SM, Hellmann NS, Fischl MA,

Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.. 2004 August 1539 (4):552-8. Epub 07/30/2004.

Comparison of versions 1.0 AND 1.5 of the UltraSensitive AMPLICOR HIV-1 MONITOR test for subjects with low viral load.

Jackson JB, Piwowar-Manning E, Johnson-Lewis L, Bassett R, Demeter LM, Brambilla D

Journal of clinical microbiology.. 2004 June 42 (6):2774-6. Epub 1900 01 01.

Detection of drug-resistant minority variants of HIV-1 during virologic failure of indinavir, lamivudine, and zidovudine.

Dykes C, Najjar J, Bosch RJ, Wantman M, Furtado M, Hart S, Hammer SM, Demeter LM

The Journal of infectious diseases.. 2004 March 15189 (6):1091-6. Epub 03/01/2004.

Update of the drug resistance mutations in HIV-1: 2004.

Johnson VA, Brun-Vézinet F, Clotet B, Conway B, D'Aquila RT, Demeter LM, Kuritzkes DR, Pillay D, Schapiro JM, Telenti A, Richman DD

Topics in HIV medicine : a publication of the International AIDS

A randomized trial of nelfinavir and abacavir in combination with efavirenz and adefovir dipivoxil in HIV-1-infected persons with virological failure receiving indinavir.

Hammer SM, Bassett R, Squires KE, Fischl MA, Demeter LM, Currier JS, Mellors JW, Morse GD, Eron JJ, Santana JL, DeGruttola V,

Antiviral therapy.. 2003 December 8 (6):507-18. Epub 1900 01 01.

Serum interferon inhibitor declines in patients with HIV-1 infection after a change in antiretroviral therapy.

Chadha KC, Schwartz SA, Nair MP, Demeter LR, Hewitt RG

Immunological investigations.. 2003 November 32 (4):299-312. Epub 1900 01 01.

A randomized trial of 2 different 4-drug antiretroviral regimens versus a 3-drug regimen, in advanced human immunodeficiency virus disease.

Fischl MA, Ribaudo HJ, Collier AC, Erice A, Giuliano M, Dehlinger M, Eron JJ, Saag MS, Hammer SM, Vella S, Morse GD, Feinberg JE, Demeter LM, Eshleman SH,

The Journal of infectious diseases.. 2003 September 1188 (5):625-34. Epub 08/15/2003.

Antiretroviral drug resistance testing in adults infected with human immunodeficiency virus type 1: 2003 recommendations of an International AIDS Society-USA Panel.

Hirsch MS, Brun-Vézinet F, Clotet B, Conway B, Kuritzkes DR, D'Aquila RT, Demeter LM, Hammer SM, Johnson VA, Loveday C, Mellors JW, Jacobsen DM, Richman DD

Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.. 2003 July 137 (1):113-28. Epub 06/23/2003.

Drug resistance mutations in HIV-1.

D'Aquila RT, Schapiro JM, Brun-Vézinet F, Clotet B, Conway B, Demeter LM, Grant RM, Johnson VA, Kuritzkes DR, Loveday C, Shafer RW, Richman DD

Topics in HIV medicine : a publication of the International AIDS

Questions to and answers from the International AIDS Society-USA Resistance Testing Guidelines Panel.

Hirsch MS, Brun-Vézinet F, Clotet B, Conway B, Kuritzkes DR, D'Aquila RT, Demeter LM, Hammer SM, Johnson VA, Loveday C, Mellors JW, Richman DD,

Topics in HIV medicine : a publication of the International AIDS

Drug resistance mutations in HIV-1.

Johnson VA, Brun-Vézinet F, Clotet B, Conway B, D'Aquila RT, Demeter LM, Kuritzkes DR, Pillay D, Schapiro JM, Telenti A, Richman DD,

Topics in HIV medicine : a publication of the International AIDS

Immune reconstitution syndrome after successful treatment of Pneumocystis carinii pneumonia in a man with human immunodeficiency virus type 1 infection.

Koval CE, Gigliotti F, Nevins D, Demeter LM

Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.. 2002 August 1535 (4):491-3. Epub 07/24/2002.

Detection of replication-competent human immunodeficiency virus type 1 (HIV-1) in cultures from patients with levels of HIV-1 RNA in plasma suppressed to less than 500 or 50 copies per milliliter.

Demeter LM, Bosch RJ, Coombs RW, Fiscus S, Bremer J, Johnson VA, Erice A, Jackson JB, Spector SA, Squires KM, Fischl MA, Hughes MD, Hammer SM

Journal of clinical microbiology.. 2002 June 40 (6):2089-94. Epub 1900 01 01.

Drug Resistance Mutations in HIV-1.

D'Aquila RT, , Schapiro JM, Brun-Vézinet F, Clotet B, Conway B, Demeter LM, Grant RM, Johnson VA, Kuritzkes DR, Loveday C, Shafer RW, Richman DD

Topics in HIV medicine : a publication of the International AIDS

Predictors of virologic and clinical outcomes in HIV-1-infected patients receiving concurrent treatment with indinavir, zidovudine, and lamivudine. AIDS Clinical Trials Group Protocol 320.

Demeter LM, Hughes MD, Coombs RW, Jackson JB, Grimes JM, Bosch RJ, Fiscus SA, Spector SA, Squires KE, Fischl MA, Hammer SM

Annals of internal medicine.. 2001 December 4135 (11):954-64. Epub 1900 01 01.

Mutation of the methylated tRNA(Lys)(3) residue A58 disrupts reverse transcription and inhibits replication of human immunodeficiency virus type 1.

Renda MJ, Rosenblatt JD, Klimatcheva E, Demeter LM, Bambara RA, Planelles V

Journal of virology.. 2001 October 75 (20):9671-8. Epub 1900 01 01.

Impact of clinical reverse transcriptase sequences on the replication capacity of HIV-1 drug-resistant mutants.

Dykes C, Fox K, Lloyd A, Chiulli M, Morse E, Demeter LM

Virology.. 2001 July 5285 (2):193-203. Epub 1900 01 01.

A Phase 1 study of a recombinant viruslike particle vaccine against human papillomavirus type 11 in healthy adult volunteers.

Evans TG, Bonnez W, Rose RC, Koenig S, Demeter L, Suzich JA, O'Brien D, Campbell M, White WI, Balsley J, Reichman RC

The Journal of infectious diseases.. 2001 May 15183 (10):1485-93. Epub 04/24/2001.

The Y181C mutant of HIV-1 reverse transcriptase resistant to nonnucleoside reverse transcriptase inhibitors alters the size distribution of RNase H cleavages.

Archer RH, Wisniewski M, Bambara RA, Demeter LM

Biochemistry.. 2001 April 340 (13):4087-95. Epub 1900 01 01.

International perspectives on antiretroviral resistance. Phenotypic and genotypic resistance assays: methodology, reliability, and interpretations.

Demeter L, Haubrich R

Journal of acquired immune deficiency syndromes : JAIDS.. 2001 March 126 Suppl 1 :S3-9. Epub 1900 01 01.

International perspectives on antiretroviral resistance. Clinical utility of resistance testing: retrospective and prospective data supporting use and current recommendations.

Haubrich R, Demeter L

Journal of acquired immune deficiency syndromes : JAIDS.. 2001 March 126 Suppl 1 :S51-9. Epub 1900 01 01.

Mutants of human immunodeficiency virus type 1 (HIV-1) reverse transcriptase resistant to nonnucleoside reverse transcriptase inhibitors demonstrate altered rates of RNase H cleavage that correlate with HIV-1 replication fitness in cell culture.

Archer RH, Dykes C, Gerondelis P, Lloyd A, Fay P, Reichman RC, Bambara RA, Demeter LM

Journal of virology.. 2000 September 74 (18):8390-401. Epub 1900 01 01.

Analysis of env sequence evolution in human immunodeficiency virus-infected patients receiving therapy with nonnucleoside reverse-transcriptase inhibitors.

Dykes C, Mootsikapun P, Dexter A, Berrios L, Chiulli M, Reichman RC, Demeter LM

The Journal of infectious diseases.. 2000 July 182 (1):316-20. Epub 07/06/2000.

Autonomic performance and dehydroepiandrosterone sulfate levels in HIV-1-infected individuals: relationship to TH1 and TH2 cytokine profile.

Schifitto G, McDermott MP, Evans T, Fitzgerald T, Schwimmer J, Demeter L, Kieburtz K

Archives of neurology.. 2000 July 57 (7):1027-32. Epub 1900 01 01.

Antiretroviral drug resistance testing in adult HIV-1 infection: recommendations of an International AIDS Society-USA Panel.

Hirsch MS, Brun-Vézinet F, D'Aquila RT, Hammer SM, Johnson VA, Kuritzkes DR, Loveday C, Mellors JW, Clotet B, Conway B, Demeter LM, Vella S, Jacobsen DM, Richman DD

JAMA.. 2000 May 10283 (18):2417-26. Epub 1900 01 01.

Delavirdine susceptibilities and associated reverse transcriptase mutations in human immunodeficiency virus type 1 isolates from patients in a phase I/II trial of delavirdine monotherapy (ACTG 260).

Demeter LM, Shafer RW, Meehan PM, Holden-Wiltse J, Fischl MA, Freimuth WW, Para MF, Reichman RC

Antimicrobial agents and chemotherapy.. 2000 March 44 (3):794-7. Epub 1900 01 01.

Concentration-targeted phase I trials of atevirdine mesylate in patients with HIV infection: dosage requirements and pharmacokinetic studies. The ACTG 187 and 199 study teams.

Morse GD, Reichman RC, Fischl MA, Para M, Leedom J, Powderly W, Demeter LM, Resnick L, Bassiakos Y, Timpone J, Cox S, Batts D

Antiviral research.. 2000 January 45 (1):47-58. Epub 1900 01 01.

Efficacy and safety of delavirdine mesylate with zidovudine and didanosine compared with two-drug combinations of these agents in persons with HIV disease with CD4 counts of 100 to 500 cells/mm3 (ACTG 261). ACTG 261 Team.

Friedland GH, Pollard R, Griffith B, Hughes M, Morse G, Bassett R, Freimuth W, Demeter L, Connick E, Nevin T, Hirsch M, Fischl M

Journal of acquired immune deficiency syndromes : JAIDS.. 1999 August 121 (4):281-92. Epub 1900 01 01.

The P236L delavirdine-resistant human immunodeficiency virus type 1 mutant is replication defective and demonstrates alterations in both RNA 5'-end- and DNA 3'-end-directed RNase H activities.

Gerondelis P, Archer RH, Palaniappan C, Reichman RC, Fay PJ, Bambara RA, Demeter LM

Journal of virology.. 1999 July 73 (7):5803-13. Epub 1900 01 01.

Worldwide evaluation of DNA sequencing approaches for identification of drug resistance mutations in the human immunodeficiency virus type 1 reverse transcriptase.

Schuurman R, Demeter L, Reichelderfer P, Tijnagel J, de Groot T, Boucher C

Journal of clinical microbiology.. 1999 July 37 (7):2291-6. Epub 1900 01 01.

Association of human papillomavirus infection and disease with magnitude of human immunodeficiency virus type 1 (HIV-1) RNA plasma level among women with HIV-1 infection.

Luque AE, Demeter LM, Reichman RC

The Journal of infectious diseases.. 1999 June 179 (6):1405-9. Epub 1900 01 01.

ACTG 260: a randomized, phase I-II, dose-ranging trial of the anti-human immunodeficiency virus activity of delavirdine monotherapy. The AIDS Clinical Trials Group Protocol 260 Team.

Para MF, Meehan P, Holden-Wiltse J, Fischl M, Morse G, Shafer R, Demeter LM, Wood K, Nevin T, Virani-Ketter N, Freimuth WW

Antimicrobial agents and chemotherapy.. 1999 June 43 (6):1373-8. Epub 1900 01 01.

Interlaboratory concordance of DNA sequence analysis to detect reverse transcriptase mutations in HIV-1 proviral DNA. ACTG Sequencing Working Group. AIDS Clinical Trials Group.

Demeter LM, D'Aquila R, Weislow O, Lorenzo E, Erice A, Fitzgibbon J, Shafer R, Richman D, Howard TM, Zhao Y, Fisher E, Huang D, Mayers D, Sylvester S, Arens M, Sannerud K, Rasheed S, Johnson V, Kuritzkes D, Reichelderfer P, Japour A

Journal of virological methods.. 1998 November 75 (1):93-104. Epub 1900 01 01.

Phase I study of atevirdine mesylate (U-87201E) monotherapy in HIV-1-infected patients.

Demeter LM, Meehan PM, Morse G, Fischl MA, Para M, Powderly W, Leedom J, Holden-Wiltse J, Greisberger C, Wood K, Timpone J, Wathen LK, Nevin T, Resnick L, Batts DH, Reichman RC

Journal of acquired immune deficiency syndromes and human

Antiretroviral drug resistance testing in adults with HIV infection: implications for clinical management. International AIDS Society--USA Panel.

Hirsch MS, Conway B, D'Aquila RT, Johnson VA, Brun-Vézinet F, Clotet B, Demeter LM, Hammer SM, Jacobsen DM, Kuritzkes DR, Loveday C, Mellors JW, Vella S, Richman DD

JAMA.. 1998 June 24279 (24):1984-91. Epub 1900 01 01.

A controlled trial of two nucleoside analogues plus indinavir in persons with human immunodeficiency virus infection and CD4 cell counts of 200 per cubic millimeter or less. AIDS Clinical Trials Group 320 Study Team.

Hammer SM, Squires KE, Hughes MD, Grimes JM, Demeter LM, Currier JS, Eron JJ, Feinberg JE, Balfour HH, Deyton LR, Chodakewitz JA, Fischl MA

The New England journal of medicine.. 1997 September 11337 (11):725-33. Epub 1900 01 01.

HIV-1 drug susceptibilities and reverse transcriptase mutations in patients receiving combination therapy with didanosine and delavirdine.

Demeter LM, Meehan PM, Morse G, Gerondelis P, Dexter A, Berrios L, Cox S, Freimuth W, Reichman RC

Journal of acquired immune deficiency syndromes and human

Longitudinal analysis of quantitative virologic measures in human immunodeficiency virus-infected subjects with > or = 400 CD4 lymphocytes: implications for applying measurements to individual patients. National Institute of Allergy and Infectious Diseases AIDS Vaccine Evaluation Group.

Paxton WB, Coombs RW, McElrath MJ, Keefer MC, Hughes J, Sinangil F, Chernoff D, Demeter L, Williams B, Corey L

The Journal of infectious diseases.. 1997 February 175 (2):247-54. Epub 1900 01 01.

Prognostic value of plasma human immunodeficiency virus type 1 (HIV-1) RNA levels in patients with advanced HIV-1 disease and with little or no prior zidovudine therapy. AIDS Clinical Trials Group Protocol 116A/116B/117 Team.

Welles SL, Jackson JB, Yen-Lieberman B, Demeter L, Japour AJ, Smeaton LM, Johnson VA, Kuritzkes DR, D'Aquila RT, Reichelderfer PA, Richman DD, Reichman R, Fischl M, Dolin R, Coombs RW, Kahn JO, McLaren C, Todd J, Kwok S, Crumpacker CS

The Journal of infectious diseases.. 1996 October 174 (4):696-703. Epub 1900 01 01.

Therapeutic efficacy and complications of excisional biopsy of condyloma acuminatum.

Bonnez W, Oakes D, Choi A, d'Arcy SJ, Pappas PG, Corey L, Stoler MH, Demeter LM, Reichman RC

Sexually transmitted diseases.. 1996 23 (4):273-6. Epub 1900 01 01.

Development of zidovudine resistance mutations in patients receiving prolonged didanosine monotherapy.

Demeter LM, Nawaz T, Morse G, Dolin R, Dexter A, Gerondelis P, Reichman RC

The Journal of infectious diseases.. 1995 December 172 (6):1480-5. Epub 1900 01 01.

Effects of zidovudine use during pregnancy on resistance and vertical transmission of human immunodeficiency virus type 1.

Frenkel LM, Wagner LE, Demeter LM, Dewhurst S, Coombs RW, Murante BL, Reichman RC

Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.. 1995 May 20 (5):1321-6. Epub 1900 01 01.

Phase I study of atevirdine, a nonnucleoside reverse transcriptase inhibitor, in combination with zidovudine for human immunodeficiency virus type 1 infection. ACTG 199 Study Team.

Reichman RC, Morse GD, Demeter LM, Resnick L, Bassiakos Y, Fischl M, Para M, Powderly W, Leedom J, Greisberger C

The Journal of infectious diseases.. 1995 February 171 (2):297-304. Epub 1900 01 01.

Induction of proliferating cell nuclear antigen in differentiated keratinocytes of human papillomavirus-infected lesions.

Demeter LM, Stoler MH, Broker TR, Chow LT

Human pathology.. 1994 April 25 (4):343-8. Epub 1900 01 01.

Penile intraepithelial neoplasia: clinical presentation and an analysis of the physical state of human papillomavirus DNA.

Demeter LM, Stoler MH, Bonnez W, Corey L, Pappas P, Strussenberg J, Reichman RC

The Journal of infectious diseases.. 1993 July 168 (1):38-46. Epub 1900 01 01.

Production of human papillomavirus and modulation of the infectious program in epithelial raft cultures. OFF.

Dollard SC, Wilson JL, Demeter LM, Bonnez W, Reichman RC, Broker TR, Chow LT

Genes & development.. 1992 July 6 (7):1131-42. Epub 1900 01 01.

Expression of high-affinity laminin receptor mRNA correlates with cell proliferation rather than invasion in human papillomavirus-associated cervical neoplasms.

Demeter LM, Stoler MH, Sobel ME, Broker TR, Chow LT

Cancer research.. 1992 March 1552 (6):1561-7. Epub 1900 01 01.

Treatment of condyloma acuminatum with three different interferon-alpha preparations administered parenterally: a double-blind, placebo-controlled trial.

Reichman RC, Oakes D, Bonnez W, Brown D, Mattison HR, Bailey-Farchione A, Stoler MH, Demeter LM, Tyring SK, Miller L

The Journal of infectious diseases.. 1990 December 162 (6):1270-6. Epub 1900 01 01.

Books

AIDS Therapy (2006)

Chapter: Delavirdine

Authors: Demeter LM, Reichman RC

Publisher: Churchill Livingstone, New York 2006

Principles and Practice of Infectious Diseases (2005)

Chapter: JC, BK, and other polyomaviruses; Progressive multifocal leukoencephalopathy

Authors: Demeter LM

Publisher: Churchill Livingstone, New York 2005

AIDS Therapy (2000)

Chapter: Delavirdine

Authors: Demeter LM, Reichman RC

Publisher: Churchill Livingstone, New York 2000

Principles and Practice of Infectious Diseases (2000)

Chapter: Detection of HIV infection

Authors: Demeter LM, Reichman RC

Publisher: Churchill Livingstone, New York 2000

Principles and Practice of Infectious Diseases (2000)

Chapter: JC, BK, and other polyomaviruses; Progressive multifocal leukoencephalopathy

Authors: Demeter LM

Publisher: Churchill Livingstone, New York 2000

AIDS Therapy (1999)

Chapter: Delavirdine

Authors: Demeter LM, Reichman RC

Publisher: Churchill Livingstone, New York 1999

Principles and Practice of Infectious Diseases (1995)

Chapter: JC, BK, and other polyomaviruses; Progressive multifocal leukoencephalopathy

Authors: Demeter LM

Publisher: Churchill Livingstone, New York 1995

Genital Warts--Human Papillomavirus Infection (1994)

Chapter: Association of human papillomaviruses with other female genital tract tumors

Authors: Demeter LM, Reichman RC

Publisher: Edward Arnold Publishers, Ltd., London 1994

Practical Diagnosis of Viral infections (1993)

Chapter: Diagnosis of anogenital human papillomavirus infections

Authors: Demeter LM, Reichman RC

Publisher: Raven Press, New York 1993